NCT04480853View on ClinicalTrials.gov

Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis

PHASE4RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 12, 2020

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
Multiple Sclerosis
Interventions
DRUG

Fingolimod

Fingolimod 0.5 mg QD, oral

Trial Locations (6)

10002

RECRUITING

Novartis Investigative Site, Taipei

11220

WITHDRAWN

Novartis Investigative Site, Taipei

33305

WITHDRAWN

Novartis Investigative Site, Taoyuan District

70403

RECRUITING

Novartis Investigative Site, Tainan City

83301

RECRUITING

Novartis Investigative Site, Kaohsiung City

407219

RECRUITING

Novartis Investigative Site, Taichung

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY